Parkman Healthcare Partners LLC Takes $14.60 Million Position in Envista Holdings Corporation $NVST

Parkman Healthcare Partners LLC acquired a new position in Envista Holdings Corporation (NYSE:NVST) during the 2nd quarter, according to its most recent filing with the SEC. The fund acquired 553,916 shares of the company’s stock, valued at approximately $14,596,000. Envista makes up about 1.5% of Parkman Healthcare Partners LLC’s holdings, making the stock its 27th largest holding. Parkman Healthcare Partners LLC owned about 0.34% of Envista as of its most recent SEC filing.

A number of other large investors have also recently added to or reduced their stakes in NVST. Legal & General Group Plc purchased a new position in Envista during the 2nd quarter valued at about $5,987,000. The Manufacturers Life Insurance Company acquired a new stake in shares of Envista in the second quarter valued at approximately $2,828,000. Algert Global LLC increased its stake in shares of Envista by 5.0% during the 2nd quarter. Algert Global LLC now owns 657,381 shares of the company’s stock worth $17,322,000 after purchasing an additional 31,346 shares in the last quarter. Sanctuary Advisors LLC purchased a new position in shares of Envista during the 2nd quarter worth approximately $290,000. Finally, Globeflex Capital L P acquired a new position in shares of Envista during the 2nd quarter worth approximately $823,000.

Insider Activity

In related news, SVP Mischa Reis sold 8,000 shares of the business’s stock in a transaction that occurred on Thursday, August 20th. The shares were sold at an average price of $27.50, for a total value of $220,000.00. Following the completion of the sale, the senior vice president directly owned 27,321 shares in the company, valued at approximately $751,327.50. The trade was a 22.65% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Corporate insiders own 0.99% of the company’s stock.

Analysts Set New Price Targets

A number of equities research analysts have commented on NVST shares. Piper Sandler reiterated a “neutral” rating and set a $28.00 target price (up from $26.00) on shares of Envista in a report on Thursday, August 6th. BMO Capital Markets initiated coverage on shares of Envista in a research note on Wednesday, July 8th. They set a “market perform” rating and a $27.00 price target on the stock. Wall Street Zen upgraded shares of Envista from a “buy” rating to a “strong-buy” rating in a report on Saturday. Evercore reissued an “outperform” rating and issued a $33.00 price objective on shares of Envista in a research report on Thursday, May 7th. Finally, Weiss Ratings raised shares of Envista from a “hold (c-)” rating to a “hold (c)” rating in a research note on Thursday, August 6th. One investment analyst has rated the stock with a Strong Buy rating, six have issued a Buy rating and nine have issued a Hold rating to the stock. Based on data from MarketBeat, Envista presently has a consensus rating of “Moderate Buy” and an average price target of $29.31.

Envista Stock Performance

NYSE NVST opened at $27.34 on Tuesday. The business’s 50-day moving average price is $26.95 and its 200 day moving average price is $26.33. The company has a current ratio of 2.43, a quick ratio of 2.07 and a debt-to-equity ratio of 0.47. Envista Holdings Corporation has a twelve month low of $18.77 and a twelve month high of $30.42. The company has a market capitalization of $4.39 billion, a PE ratio of 47.15, a price-to-earnings-growth ratio of 1.30 and a beta of 0.86.

Envista (NYSE:NVST) last posted its quarterly earnings results on Wednesday, August 5th. The company reported $0.41 EPS for the quarter, beating the consensus estimate of $0.34 by $0.07. Envista had a return on equity of 7.88% and a net margin of 3.33%.The company had revenue of $730.50 million during the quarter, compared to analysts’ expectations of $716.11 million. During the same quarter in the previous year, the business earned $0.26 EPS. The firm’s revenue was up 7.1% on a year-over-year basis. Envista has set its FY 2026 guidance at 1.500-1.550 EPS. On average, research analysts predict that Envista Holdings Corporation will post 1.53 earnings per share for the current year.

Envista Company Profile

Envista Holdings Corporation is a global dental products company that develops, manufactures and markets a broad portfolio of dental consumables, equipment and technology solutions. Headquartered in Brea, California, Envista serves dental practitioners, specialists and laboratories in more than 150 countries. The company’s offerings span implant, orthodontic, endodontic and restorative product lines as well as digital imaging systems and practice management software.

Envista’s product brands include Nobel Biocare for dental implants and restorative solutions, Ormco for orthodontic appliances and treatment systems, Kerr for restorative and endodontic materials, KaVo for dental imaging and handpieces, and Vista for surgical drills and instruments.